OBJECTIVE: Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy and safety in children and adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine the 3-year efficacy and safety of atorvastatin in preventing subclinical atherosclerosis progression in pediatric-onset SLE. METHODS: A total of 221 participants with pediatric SLE (ages 10-21 years) from 21 North American sites were enrolled in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus study, a randomized double-blind, placebo-controlled clinical trial, between August 2003 and November 2006 with 36-month followup. Participants were randomized to receive atorvastatin (n=113) or placebo (n=108) at 10 or 20 mg/day depending on weight, in addition to usual care. The primary end point was progression of mean-mean common carotid intima-media thickening (CIMT) measured by ultrasound. Secondary end points included other segment/wall-specific CIMT measures, lipid profile, high-sensitivity C-reactive protein (hsCRP) level, and SLE disease activity and damage outcomes. RESULTS:Progression of mean-mean common CIMT did not differ significantly between treatment groups (0.0010 mm/year for atorvastatin versus 0.0024 mm/year for placebo; P=0.24). The atorvastatin group achieved lower hsCRP (P=0.04), total cholesterol (P<0.001), and low-density lipoprotein (P<0.001) levels compared with placebo. In the placebo group, CIMT progressed significantly across all CIMT outcomes (0.0023-0.0144 mm/year; P<0.05). Serious adverse events and critical safety measures did not differ between groups. CONCLUSION: Our results indicate that routine statin use over 3 years has no significant effect on subclinical atherosclerosis progression in young SLE patients; however, further analyses may suggest subgroups that would benefit from targeted statin therapy. Atorvastatin was well tolerated without safety concerns.
RCT Entities:
OBJECTIVE: Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy and safety in children and adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine the 3-year efficacy and safety of atorvastatin in preventing subclinical atherosclerosis progression in pediatric-onset SLE. METHODS: A total of 221 participants with pediatric SLE (ages 10-21 years) from 21 North American sites were enrolled in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus study, a randomized double-blind, placebo-controlled clinical trial, between August 2003 and November 2006 with 36-month followup. Participants were randomized to receive atorvastatin (n=113) or placebo (n=108) at 10 or 20 mg/day depending on weight, in addition to usual care. The primary end point was progression of mean-mean common carotid intima-media thickening (CIMT) measured by ultrasound. Secondary end points included other segment/wall-specific CIMT measures, lipid profile, high-sensitivity C-reactive protein (hsCRP) level, and SLE disease activity and damage outcomes. RESULTS: Progression of mean-mean common CIMT did not differ significantly between treatment groups (0.0010 mm/year for atorvastatin versus 0.0024 mm/year for placebo; P=0.24). The atorvastatin group achieved lower hsCRP (P=0.04), total cholesterol (P<0.001), and low-density lipoprotein (P<0.001) levels compared with placebo. In the placebo group, CIMT progressed significantly across all CIMT outcomes (0.0023-0.0144 mm/year; P<0.05). Serious adverse events and critical safety measures did not differ between groups. CONCLUSION: Our results indicate that routine statin use over 3 years has no significant effect on subclinical atherosclerosis progression in young SLEpatients; however, further analyses may suggest subgroups that would benefit from targeted statin therapy. Atorvastatin was well tolerated without safety concerns.
Authors: M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers Journal: BMJ Date: 2009-06-30
Authors: Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: John Robert Crouse; Diederick E Grobbee; Daniel H O'Leary; Michiel L Bots; Gregory W Evans; Mike K Palmer; Ward A Riley; Joel S Raichlen Journal: Cardiovasc Drugs Ther Date: 2004-05 Impact factor: 3.727
Authors: D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma Journal: Arthritis Rheum Date: 1996-03
Authors: Stacy P Ardoin; Laura Eve Schanberg; Christy I Sandborg; Huiman X Barnhart; Greg W Evans; Eric Yow; Kelly L Mieszkalski; Norman T Ilowite; Anne Eberhard; Lisa F Imundo; Yuki Kimura; Deborah Levy; Emily von Scheven; Earl Silverman; Suzanne L Bowyer; L Punaro; Nora G Singer; David D Sherry; Deborah K McCurdy; Marissa Klein-Gitelman; Carol Wallace; Richard M Silver; Linda Wagner-Weiner; Gloria C Higgins; Hermine I Brunner; Lawrence Jung; Jennifer B Soep; Ann M Reed; Susan D Thompson Journal: Ann Rheum Dis Date: 2013-02-22 Impact factor: 19.103
Authors: Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Maureen McMahon; Brian J Skaggs; Jennifer M Grossman; Lori Sahakian; John Fitzgerald; Weng Kee Wong; Elaine V Lourenco; Nagesh Ragavendra; Christina Charles-Schoeman; Alan Gorn; George A Karpouzas; Mihaela B Taylor; Karol E Watson; Michael H Weisman; Daniel J Wallace; Bevra H Hahn Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995